Phase | n | Mean ± SD | RAADS-14 Screen score | Internal consistency, α | |||||
---|---|---|---|---|---|---|---|---|---|
Median (range) | M-W U (z)a | r b | F1c | F2d | F3e | RAADS-14 Screen | |||
Phase II | |||||||||
ASD | 58 | 27.9 ± 11.5 | 30 (0–42) | – | – | 0.84 | 0.67 | 0.63 | 0.88 |
ADHD | 43 | 17.5 ± 9.5 | 18 (1–36)f | 596.0 (-4.5) | 0.68 | 0.80 | 0.42 | 0.51 | 0.77 |
Other psychiatric disorders | 95 | 11.9 ± 8.3 | 12 (0–39)f | 772.5 (-7.5) | 0.57 | 0.75 | 0.54 | 0.57 | 0.78 |
Non-psychiatric controls | 590 | 3.9 ± 4.6 | 3 (0–29)f | 1528 (-11.6) | 0.48 | 0.65 | 0.32 | 0.53 | 0.70 |
Total sample | 792 | 7.4 ± 9.3 | 4 (0 – 42) | – | – | 0.86 | 0.64 | 0.76 | 0.90 |
Phase III | |||||||||
ASD | 77 | 30.8 ± 8.6 | 32 (8–42) | 0.75 | 0.62 | 0.62 | 0.80 | ||
ADHD | 301 | 15.4 ± 9.3 | 15 (0–42)f | 2824 (-10.3) | 0.59 | 0.73 | 0.49 | 0.62 | 0.79 |
Other psychiatric disorders | 69 | 12.6 ± 9.3 | 11 (0–39)f | 467.5 (-8.6) | 0.71 | 0.75 | 0.40 | 0.76 | 0.84 |
Total sample | 457 | 17.4 ± 11.0 | 16 (0 – 42) | – | 0.80 | 0.58 | 0.73 | 0.86 |